PharVision Advisers’s Crown Holdings CCK Stock Holding History

PharVision Advisers’s Portfolio CCK Stock Details CCK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,016	Closed	-$414K	–	193
2025 Q4	$414K	Buy	+4,016	New	+$391K	0.21%	108
2025 Q2	–	Sell	-4,440	Closed	-$396K	–	291
2025 Q1	$396K	Buy	+4,440	New	+$387K	0.55%	34

Other funds holding CCK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

PharVision Advisers's CCK Position: Q1 2026 in Review

PharVision Advisers sold out of Crown Holdings (CCK) in Q1 2026, closing a stake of 4,016 shares — an estimated $414K sold.

PharVision Advisers first reported a position in CCK in Q1 2025 and held it in 2 quarters. The position peaked at $414K in Q4 2025. 632 funds tracked by Wall St. Rank hold CCK as of Q1 2026.

PharVision Advisers reported no remaining Crown Holdings position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 4,016 Crown Holdings shares in Q1 2026, an estimated $414K.
PharVision Advisers first reported a position in Crown Holdings in Q1 2025 and held it in 2 quarters.
PharVision Advisers's Crown Holdings position peaked at $414K in Q4 2025.
632 funds tracked by Wall St. Rank held Crown Holdings as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.